Opdivo trial stopped early as BMS med tops Afinitor in kidney cancer

Bristol-Myers Squibb ($BMY) hit a big milestone in its quest to expand use of the immunotherapy Opdivo in a slate of cancer types. In a late-stage kidney cancer study, Opdivo showed a survival advantage over Novartis' ($NVS) Afinitor, prompting a monitoring committee to stop the trial early. Release

Suggested Articles

Sanofi's Sarclisa is coming full-force at Johnson & Johnson blockbuster Darzalex in the multiple myeloma field—now backed by new data.

Merck CEO Ken Frazier has spoken passionately about racism before. Monday, amid protests over George Floyd's death, he made that passion personal.

BMS is pricing Zeposia at the wholesale acquisition cost of $86,000, lower than the tag on Novartis' in-class rival Mayzent.